Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account
 
  • new logo.jpg
    March 05, 2021 08:00 ET | Source: Immutep Limited
    Immutep Expands Part B of TACTI-002 Study

    Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...